New Delhi, Sept. 30: Pharmaceutical major Ranbaxy Laboratories today said it was open to acquisitions in the over-the-counter (OTC) segment and was evaluating some proposals.
Launching Ranbaxy Global Consumer Healthcare (RGCH), Atul Malhotra, the head of the new division said, “We are open to acquiring brands or forming strategic alliances with companies in the OTC category and are evaluating certain proposals.”
RGCH enters the market with four brands, including Revital, Pepfiz, Gesdyp and Garlic Pearls which have being moved from the prescription segment to the OTC category.
Elaborating on RGCH plans, Malhotra said the company was also planning to unveil its OTC products in countries where it already had a fast moving consumer goods marketing network including Russia, Vietnam and Myanmar.
Ranbaxy which is eyeing this segment in a big way will also unveil its herbal division next year, while its biotechnology products were slated to be launched by December.
It would source biotech products like Interferons from Cuba, Russia, China and Korea.
Company president (pharmaceuticals) Brian Tempest said the company would soon foray into the vaccine segment for which it has already forged a tie-up. He, however, declined to name the company.
As part of its FMCG marketing initiative, Ranbaxy is implementing a system of advance payment in association with HDFC.